Conversely, in patients with CCD and LVEF > 40%, the use of an SGLT2 inhibitor can be beneficial in decreasing HF hospitalizations and to improve QOL irrespective of diabetes status (COR2a).7 This evidence concerns the gene SLC5A2 and hydrops fetalis.